COMMUNIQUÉS West-GlobeNewswire

Tecan publishes 2017 Annual Report and notice of its Annual General Meeting

27/03/2018 - 07:31

Männedorf, Switzerland, March 27, 2018 - The Tecan Group (SIX Swiss Exchange: TECN) today announced the publication of its 2017 Annual Report in the Investor Relations section of the company's website at www.tecan.com [...]

Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities

27/03/2018 - 07:01

Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term interests of Novartis [...]

Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018

27/03/2018 - 07:00

Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018 HALLE (SAALE), Germany, 27 March 2018 - Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel [...]

VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN

27/03/2018 - 06:57

Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa ® in Japan Potential of Veltassa ® further validated with expansion into Japanese market Deal expands cardio-renal network with Vifor Pharma's [...]

Aslan Pharmaceuticals Files for Proposed Initial Public Offering in the U.S.

27/03/2018 - 03:00

SINGAPORE, March 26, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the [...]

Hua Medicine Raises $117.4 Million in Series D & Series E Financing

27/03/2018 - 02:00

HONG KONG and SHANGHAI, China, March 26, 2018 (GLOBE NEWSWIRE) -- Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a [...]

BioStem Technologies, Inc. Announces Letter of Intent with CCM Pharma Solutions to Co-Develop Multiple Solid to Liquid Dose Drugs Through 505(b)(2) Accelerated FDA Approval Process

27/03/2018 - 01:22

Pompano Beach, FL, March 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation providing innovative technologies with a focus in [...]

R1 Appoints Alex Mandl as Lead Director

26/03/2018 - 23:00

Steve Shulman Resigns as Chairman of the Board Bert Zimmerli Appointed as Director CHICAGO, March 26, 2018 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1” or the “Company”) (NASDAQ: RCM ), a leading provider of technology-enabled [...]

Matinas BioPharma Reports 2017 Financial Results

26/03/2018 - 22:45

BEDMINSTER, N.J., March 26, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications [...]

Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy

26/03/2018 - 22:30

GAITHERSBURG, Md., March 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced executive management changes that continue to align its organizational structure to its long-term strategy [...]

Intercept to Present at Upcoming Conference

26/03/2018 - 22:30

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]

Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction

26/03/2018 - 22:15

Verification & Validation (“V&V”) “head-to-head” data exceeds target concordance for blood grouping Overall concordance for antigen typing – 99.8%, demonstrating robustness of the MosaiQ platform Completion of [...]

Eyenovia Appoints Three Industry Veterans to Board of Directors

26/03/2018 - 22:05

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN ), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to [...]

AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients

26/03/2018 - 22:05

46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut challenge at 14 days after a single dose of ANB020 compared to zero percent dosed with placebo Concomitant [...]

Quotient Limited Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer

26/03/2018 - 22:05

JERSEY, Channel Islands, March 26, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT ), a commercial-stage diagnostics company, today announced the retirement of Paul Cowan as its Chairman and Chief Executive [...]

Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website

26/03/2018 - 22:05

NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL ), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing [...]

DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering

26/03/2018 - 22:02

Montrouge, France, March 26, 2018 DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering DBV Technologies (the "Company") (Euronext: DBV - ISIN: FR0010417345 - Nasdaq [...]

DBV Technologies annonce le règlement-livraison des actions ordinaires supplémentaires au titre de l'exercice de la totalité de l'option de surallocation dans le cadre de son offre globale

26/03/2018 - 22:02

Montrouge, France, le 26 Mars (22h00 CEST), 2018 DBV Technologies annonce le règlement-livraison des actions ordinaires supplémentaires au titre de l'exercice de la totalité de l'option de surallocation dans le cadre de [...]

argenx announces Annual General Meeting of Shareholders on May 8, 2018

26/03/2018 - 22:01

March 26, 2018 Breda, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe [...]